Conversely, a bioinformatics analysis published about specific Treg-targeted antibodies reported that GITR did not meet the criteria for overexpression in liver carcinoma, in contrast to its overexpression observed in other malignancies such as squamous non-small cell lung cancer (NSCLC), renal cell carcinoma, breast infiltrating ductal carcinoma, ovarian serous carcinoma, and clear cell carcinoma [90]. Here, TNFRSF18 is linked to hepatocellular carcinoma.